<DOC>
	<DOCNO>NCT01523457</DOCNO>
	<brief_summary>The primary objective study determine progression free survival patient metastatic pancreatic cancer patient locally advance unresectable non-metastatic pancreatic cancer treat dose-attenuated modification folinic acid , fluorouracil , irinotecan , oxaliplatin ( FOLFIRINOX ) . Secondary endpoint include : determine objective response rate accord RECIST ; determine overall survival ; evaluate toxicity ; determine rate resection locally advance unresectable stratum ; correlate time progression , objective response , overall survival early change glucose metabolism use [ 18F ] -fluorodeoxyglucose ( FDG ) -positron emission tomography ( PET ) scanning .</brief_summary>
	<brief_title>Study Modified FOLFIRINOX Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Pathologic cytologic documentation pancreatic adenocarcinoma Metastatic locally advance unresectable disease , include borderline unresectable disease Patients biliary gastroduodenal obstruction must drainage surgical bypass prior start chemoradiation Measurable nonmeasurable assessable disease No prior treatment ( chemotherapy , biological therapy , radiotherapy ) metastatic nonmetastatic locally advanced unresectable pancreatic cancer 6 month since completion prior neoadjuvant adjuvant therapy ( chemotherapy radiotherapy ) resect pancreatic cancer No prior treatment oxaliplatin irinotecan No prior treatment fluoruouracil capecitabine unless administer radiosensitizing drug adjuvant/neoadjuvant chemoradiotherapy after/before resection pancreatic cancer Patients receive chemotherapy &gt; 2 year ago malignancy pancreatic cancer eligible , provide chemotherapy complete &gt; 2 year ago evidence second malignancy time study entry &gt; 4 week since major surgery No concurrent anticancer therapy ECOG Performance Status : 01 Age &gt; 18 No malignancy within past two year except basal cell carcinoma skin , cervical carcinoma situ , nonmetastatic prostate cancer Paraffin block slide must available Adequate organ function No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No &gt; grade 1 sensory peripheral neuropathy No uncontrolled seizure disorder , active neurological disease , know CNS disease No significant cardiac disease , include follow : unstable angina , New York Heart Association class IIIV congestive heart failure , myocardial infarction within six month prior study enrollment No history chronic diarrhea Not pregnant nursing No medical condition reason , opinion investigator , would preclude study participation Laboratory parameter follow : absolute neutrophil count ≥ 1,500/uL , platelet count ≥ 100,000/uL , hemoglobin ≥ 9 g , /dL , creatinine &lt; 1.5 X ULN estimate GFR &gt; 30 ml/min , bilirubin &lt; 1.5 X ULN , AST ALT &lt; 3 X ULN , negative pregnancy test woman childbearing age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>locally advanced pancreatic cancer</keyword>
	<keyword>FOLFIRINOX</keyword>
	<keyword>phase II</keyword>
	<keyword>progression free survival</keyword>
</DOC>